Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mateusz Guzik has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Jan Biegus

    Department of Cardiology, Clinical Department of Intensive Cardiac Care, Faculty of Medicine, Wroclaw Medical University, Institute of Heart Diseases , Borowska 213, Wroclaw 50-556

    13 shared publications
  • Piotr Ponikowski

    Department of Cardiology, Wroclaw Medical University , Wrocław

    10 shared publications
  • Gracjan Iwanek

    Clinical Department of Intensive Cardiac Care, Department of Cardiology, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University , Wroclaw

    9 shared publications
  • Robert Zymliński

    Department of Cardiology, Clinical Department of Intensive Cardiac Care, Wroclaw Medical University, Faculty of Medicine, Institute of Heart Diseases , Borowska 213, Wroclaw 50-556

    8 shared publications
  • Robert Zymliński

    Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland

    6 shared publications
  • Jan Biegus

    Clinical Department of Intensive Cardiac Care, Department of Cardiology, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University , Wroclaw

    5 shared publications

Latest Publications

  • Open Access

    Redefining Cardiometabolic Disease: Expert Consensus on the CardioVascular–Kidney–Liver–Metabolic (CVKLM) Multiorgan Staging

    by Guillaume Baudry, Jan Biegus, Juan Carlos López-Azor, Biykem Bozkurt, Javed Butler, Marta Cobo-Marcos, Jeroen Dauw, Sven Francque, Nicolas Girerd, Jennifer B Green, et al.

    Cardiometabolic diseases increasingly manifest as interconnected dysfunction across the heart, vasculature, kidneys, liver, and metabolic system. The global rise in obesity, insulin resistance, and diabetes, together with therapies benefiting multiple organs, has reshaped the epidemiology and understanding of cardiometabolic disease, exposing the limitations of organ-specific or single-stage approaches. The cardioVascular–kidney–liver–metabolic (CVKLM) framework is a multidimensional staging system in which cardiac, vascular, kidney, liver, and metabolic involvement are graded independently from absent to advanced. Analogous to tumour–node–metastasis staging, it provides a standardized language describing disease severity within each organ and its distribution across organs. Rather than replacing existing classifications, CVKLM integrates universal heart failure stages, validated vascular risk assessment, KDIGO chronic kidney disease stratification, contemporary metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced liver disease criteria, and current definitions of diabetes and clinical obesity. Unlike hierarchical frameworks assigning a single overall stage, CVKLM preserves organ-specific information and records coexisting abnormalities across domains. Intended for clinical and research phenotyping and staging rather than as a validated global risk score, it may facilitate systematic recognition of concomitant organ disease, support existing organ-specific diagnostic, referral, and treatment pathways, and provide a standardized taxonomy for observational studies and clinical trials. The prognostic significance of CVKLM profiles, their incremental value beyond established risk tools, and their clinical utility remain to be established. By integrating these domains within a common architecture, CVKLM offers a pragmatic framework spanning the full spectrum of cardiometabolic disease, from preclinical involvement to advanced multiorgan failure.

  • The complexity of congestion in heart failure: a critical review of the evidence and a proposal for a multimodality approach

    by Alberto Palazzuoli, Nicolas Girerd, Massimo Piepoli, Andrew P Ambrosy, Guillaume Baudry, Juan Carlos Lopez-Azor, Mateusz Guzik, Òscar Miró, Jeroen Dauw, Gracian Iwanek, et al.

    Congestion remains the first cause of hospitalization in acute heart failure patients, and it is the primary goal of treatment during early phases of hospitalization. Despite its clinical relevance, a universal algorithm for quantification or characterization is lacking. Indeed, congestion has been differently evaluated across several studies in terms of timing checks and diagnostic methods. Recent analyses have highlighted the importance of differentiating between intravascular and tissue congestion. Although it is associated with haemodynamic dysfunction, extravascular congestion may occur even in the absence of overt intravascular fluid overload. Importantly, tissue congestion is not merely a reflection of intravascular volume expansion. In this framework, the interstitial space surrounding the capillary barrier and its integrity may be accounted as additive drivers for tissue congestion. In clinical practice, this distinction remains anchored in simplistic clinical assessment, and poorly evaluated. A critical review of the evidences has been performed and multimodal approaches combining ultrasonography, invasive measurements, and biomarkers have been proposed.

  • Urinary biomarker thresholds to detect diuretic resistance and insufficient diuretic response in acute heart failure

    by Jan Biegus, Gracjan Iwanek, Jeffrey Testani, Robert Zymliński, Julio Nuniez, Matteo Pagnesi, Berenika Jankowiak, Mateusz Guzik, Rafał Tymków, Amadeusz Oleszczak, et al.

    Aims: Identification of poor diuretic response is central in acute heart failure (AHF), yet the recommended post-diuretic urine sodium (uNa+) thresholds have neither been prospectively derived nor validated. We aimed to derive and validate clinically actionable urinary biomarker thresholds to identify inadequate diuretic response. Methods: This is prospective derivation-validation study. Optimal thresholds were determined based on spot urinary biomarkers measured 2 h after loop diuretic administration and 6 h diuresis. Diuretic resistance was defined as urine output < 500 mL/6 h, and insufficient diuretic response as <1000 mL/6h. Results: In the derivation cohort (n = 336), optimal uNa thresholds were <60 and <90 mmol/L. For diuretic resistance, uNa+ < 60 mmol/L showed .80 [95% confidence interval (CI): .65-.90] sensitivity, .94 (95% CI: .90-.96) specificity, and an area under the curve of .93 (95% CI: .90-.97). For insufficient diuretic response, uNa+ < 90 mmol/L showed .80 (95% CI: .69-.86) sensitivity, .84 (95% CI: .787-.878) specificity, and an area under the curve of .86 (95% CI: .83-.93). In the validation cohort (n = 141), uNa+ < 60 mmol/L had numerically higher sensitivity than uNa+ < 50 mmol/L [.87 (95% CI: .62-.98) vs. .73 (95% CI: .48-.89)], with similar specificity [.94 (95% CI: .89-.97) vs. .97 (95% CI: .92-.99)] for diuretic resistance. For insufficient diuretic response, uNa+ < 90 mmol/L had higher sensitivity (.86, 95% CI: .71-.94) than lower thresholds, with a specificity of .83 (95% CI: .75−.89). Conclusion: Data-derived post-diuretic uNa+ thresholds of <60 and <90 mmol/L identify diuretic resistance and insufficient diuretic response, respectively. Further research and external validation are needed.


  • Open Access

    Device therapies in cardiorenal syndrome: an expert review

    by Jeroen Dauw, Guillaume Baudry, Marta Cobo Marcos, Mateusz Guzik, Juan Carlos Lopez, Biykem Bozkurt, Gracjan Iwanek, Masatake Kobayashi, Òscar Miró, Peder Langeland Myhre, et al.

    Managing cardiorenal syndrome in acute decompensated heart failure remains a major challenge in contemporary cardiology. While pharmacological decongestion with diuretics is the cornerstone of therapy and is effective in most patients, worsening renal function and diuretic resistance continue to pose challenges in selected cases. Device-based therapies are increasingly explored to target key pathophysiological mechanisms underlying cardiorenal dysfunction. This expert review builds on a conceptual framework for device-based therapies. Rather than cataloguing individual technologies, we apply a functional framework that classifies devices according to their primary mode of action: reduction of venous or lymphatic congestion (‘pullers’), augmentation of arterial perfusion (‘pushers’), and direct removal of sodium and/or fluid (‘removers’). For each category, we integrate pathophysiological rationale with available clinical evidence, highlighting the predominance of early-phase physiological evidence and the need for randomized studies demonstrating benefit beyond optimized contemporary medical care.

  • Open Access

    A Machine-Learning Model for Accurate Diuresis Prediction in Acute Heart Failure (DRC-AHF).

    by Gracjan Iwanek, Mateusz Guzik, Amadeusz Oleszczak, Iga Karbowiak, Dominik Marciniak, Matteo Pagnesi, Julio Nuñez, Robert Zymliński, Piotr Ponikowski, Jan Biegus

    Aims: We aimed to develop a machine learning-based tool for accurate quantitative prediction of diuretic response in acute heart failure (AHF). Methods: We prospectively enrolled 296 AHF patients (20% female, mean age 68 ± 13 years, mean eGFR 62 ± 30 ml/min/1.73m2, median NT-proBNP 7112 [4082–14400] pg/ml) in a single-centre derivation/validation study. A Random Forest regression model was developed using derivation (n=50) and optimization (n=246) cohorts and externally validated in an independent cohort (n=50; mean age 69 ± 14 years, mean eGFR 56 ± 27 ml/min/1.73m2). Predictors were eGFR, spot urine sodium (uNa), and urine creatinine (uCr) obtained 2 hours after intravenous furosemide. Results: In the validation cohort (n=50), the median observed 6-hour urine output was 1220 [950–1750] ml vs. model-estimated 1446 [957–1749] ml (p=0.480). Observed and estimated values showed a strong positive correlation (r=0.90, 95% CI: 0.83–0.94, p<0.0001), with a mean absolute error (MAE) of 413 ml and a mean bias of 67 ± 383 ml on Bland–Altman analysis. The model correctly classified 44/50 patients (88%) into predefined diuresis categories (≤900 ml, 900–1800 ml, ≥1800 ml), compared with 58% for the reference Natriuretic Response Prediction Equation (NRPE). MAE decreased progressively by approximately 200 ml per 100 additional patients, confirming data-driven performance improvement. Conclusions: A three-variable machine learning model (eGFR, uNa, uCr at 2 hours post-diuretic) predicted 6-hour urine output with high accuracy in AHF and demonstrated adaptive improvement with expanding training data. The calculator is freely available at https://diuresis.umw.edu.pl.


  • Open Access

    Adipokine profile in acute heart failure: associations with natriuretic response and prognosis

    by Jan Biegus, Rafał Tymków, Gracjan Iwanek, Robert Zymliński, Mateusz Guzik, Magdalena Hurkacz, Wojciech Sopyla, Piotr Gajewski, Piotr Ponikowski

    Introduction: Adipose tissue signalling is linked to heart failure (HF), but its role in acute HF (AHF), especially concerning early diuretic response, is unclear. Early natriuretic response to loop diuretics is vital for effective decongestion.The objective was to characterize and evaluate the associations between circulating adipokine profiles, early natriuretic response, and clinical outcomes in AHF. Methods: We conducted a prospective observational study including 262 consecutive AHF patients. Early diuretic response was assessed by measuring post-diuretic spot urine sodium (uNa+) 2 h after intravenous loop diuretic administration. Associations between adipokines and uNa+ were assessed, and an adipokine score was constructed based on markers associated with uNa+. Clinical outcomes (all-cause mortality and a composite of death or HF hospitalization) were evaluated over 1 year using Cox regression models. Results: Patients with impaired natriuretic response (uNa+ < 90 mmol/L) exhibited higher levels of selected Domain-3 adipokines, including chemerin and FABP4. Individual adipokines showed modest associations with early natriuretic response. Visfatin was significantly associated with lower post-diuretic uNa+, while IL-6, FABP4, and Adipsin demonstrated directional but non-significant trends. An adipokine score integrating these selected adipokines was independently associated with uNa+ after multivariable adjustment (β 3.37, 95% CI 1.51–5.23; P < .001). During a 1-year follow-up, several adipokines: IL-6, resistin, and FABP4, were independently associated with mortality, while FABP4 consistently demonstrated associations with both impaired natriuresis and adverse outcomes. Conclusions: In AHF, individual adipokines are modestly associated with the early natriuretic response, whereas an integrated adipose-inflammatory profile shows a more consistent association with sodium excretion and adverse outcomes. These findings suggest that adipokine signalling may reflect biological pathways associated with diuretic response and prognosis, though the results should be considered hypothesis-generating.


  • Open Access

    Evaluation of Body Position Association with Diuretic Response and Neurohormonal Activation in Patients with Acutely Decompensated Heart Failure

    by Mateusz Guzik, Rafał Tymków

    Background/Objectives: Hemodynamic and neurohormonal factors, including renal perfusion and venous pressure, may affect diuretic response, which may be modulated by body position. This study aimed to assess whether supine versus upright positioning influences diuretic efficacy and neurohormonal activation during early decongestion in patients with AHF and reduced ejection fraction (HFrEF). Methods: This single-center, prospective, pilot randomized study enrolled 12 hospitalized patients with decompensated HFrEF receiving guideline-directed medical therapy. Participants were randomized (1:1) to remain in either the supine or upright/seated position during intravenous furosemide administration (1 mg/kg: half of the dose administered as a bolus, half as a 2-h infusion). Serial measurements of urine volume, electrolyte excretion, and neurohormonal biomarkers (renin, aldosterone, catecholamines) were performed at baseline, 2, and 6 h after diuretic administration. Results: No significant differences were found between supine and upright groups in total urine output, urine dilution, sodium excretion, or weight change after 6 h. There were no statistically significant differences in renin and aldosterone levels across subsequent timepoints; however, renin concentration tended to be higher in upright than in supine individuals. Interestingly, supine participants demonstrated greater urinary adrenaline concentration after furosemide administration, alone and after adjustment for urinary creatinine. Conclusions: No clinically meaningful differences were found between supine versus upright position patients with AHF, receiving neurohormonal blockade.

  • Open Access

    The impact of volume and sodium chloride supplementation on diuretic response during decongestion of decompensated heart failure patients

    by Gracjan Iwanek, Robert Zymliński, Mateusz Guzik, Piotr Gajewski, Julio Nuñez, Rafał Tymków, Jeffrey Testani, Piotr Ponikowski, Jan Biegus

    Background: For many years, fluid and sodium restriction have been considered an essential strategy for achieving effective decongestion in acute heart failure (AHF), but this paradigm has recently been questioned. This analysis aims to evaluate and compare the effectiveness of three different fluid strategies for decongestion: no fluid, fluid with sodium/chloride, and fluid without sodium/chloride in AHF. Methods and results: This post-hoc analysis of two prospective, single-center, mechanistic studies included 55 patients with AHF and fluid overload. All patients received standardized furosemide dosing. A total of 21 patients received a continuous infusion of 0.9% NaCl (83 mL/h), 19 patients received 5% glucose (83 mL/h), and 15 did not receive any fluids. The primary outcome is urine volume and natriuresis at 6 hours after loop diuretic administration. There was a significant difference in cumulative (6 hours) net natriuresis between patients receiving fluid therapy (n=40) and those without fluid therapy (n=15) (139 [66-264] mmol vs. 79 [15-144]mmol, p=0.043). There was no significant difference in cumulative net diuresis between these groups (1170 [880-1890]mL vs. 1010 [475-1270]mL, p = 0.078), respectively. The NaCl group had a better diuretic response when compared to the glucose and no fluids groups (absolute: 1980 [1620-3150]mL vs. 1510 [1075-2175]mL vs. 1010 [475-1270]mL, p<0.001, net: 1480 [1120-2650]mL vs. 1010 [575-1675]mL vs. 1010 [475-1270]mL, p=0.019, respectively) but the difference in natriuresis did not meet statistical significance (p=0.126). Conclusions: Intravenous fluid replacement during decongestion in patients with AHF was associated with increased net natriuresis and a trend toward higher urine output, with a significant augmentation of diuresis with sodium chloride supplementation.


  • Open Access

    The impact of pre- and post-diuretic urine osmolarity and serum osmolarity on one-year outcomes in acute heart failure patients during early decongestion

    by Mateusz Guzik, Mateusz Garus, Gracjan Iwanek, Piotr Gajewski, Natalia Kierbiedź-Guzik, Marta Rosiek-Biegus, Grzegorz Kubielas, Robert Zymliński, Piotr Ponikowski, Jan Biegus

    Background: Osmolarity is a key indicator of the balance between water and osmotically active molecules. It plays a crucial role in the diuretic response among patients with congestion in acute heart failure (AHF), and therefore, it may provide clinically meaningful information. Aims: This study investigated the association between urine (pre-and post-diuretic) and serum osmolarity during early diuretic treatment and one-year outcomes in AHF patients. Methods: It was single-center, prospective, observational study that included AHF. The patients were recruited between March 2021 and November 2023 and underwent one-year follow-up. Serum and urine osmolarity and their contributors (sodium, urea, glucose) were measured before loop diuretic exposure and 3 hours after infusion start. The main endpoints included: 1) all-cause mortality and 2) all-cause unplanned rehospitalizations. Results: In a one-year follow-up, 59 (23%) patients died (26 [10%] during index hospitalization), and 95 (40%) were rehospitalized. Higher pre-diuretic urine osmolarity was independently associated with a lower probability for mortality (hazard ratio [HR], 0.95; 95% confidence interval [CI], 0.93-0.98; P <0.01) and rehospitalization (HR, 0.98; 95% CI, 0.95-0.99; P = 0.03). Pre-diuretic urine osmolarity was significantly lower in patients with an event during follow-up (359 [272-403] vs. 419 [332-509] mOsm/l; P <0.001 for mortality and 384 [303-463] vs. 430 [342-524] mOsm/l; P = 0.03 for rehospitalization). Moreover, the degree of urine osmolarity drop was lower in patients who died (32 [8-77] vs. 122 [50-208] mOsm/l; P <0.001) and significantly influenced death probability (0.93 [0.89-0.97]; P <0.01), while significance was not proven regarding rehospitalizations (0.98 [0.95-1.00]; P = 0.16). Serum and post-diuretic urine osmolarity had no prognostic significance. Conclusions: Pre-diuretic urine osmolarity and the degree of its decrease (reflecting the potential for urine dilution) during early decongestion are associated with one-year outcomes in AHF.